Cardiovascular Risk Factors in Chronic Lymphocytic Leukemia: Early Diagnosis and Prevention Options

Résumé fourni par la source

This review presents current information on cardiovascular risk factors and the course of cardiovascular diseases (CVD) in patients with chronic lymphocytic leukemia (CLL). It also examines comorbidity in patients with CLL and the pathogenetic mechanisms common to both CLL and CVD, including chronic inflammation, endothelial dysfunction, and oxidative stress, including those mediated by viral agents. The need for antitumor treatment is associated with the risk of developing cardiovascular complications (cardiotoxicity). Current approaches to the early detection and prevention of cardiotoxicity in CLL are presented. These approaches will potentially change approaches to cardiovascular risk stratification in patients with CLL, develop an algorithm for dynamic monitoring and timely cardioprotection, including for subclinical changes in myocardial function, preventing disease progression. A multidisciplinary teamwork between a cardiologist and an oncohematologist will reduce the risk of cardiovascular complications in patients with CLL and improve their prognosis.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.